{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:05:03Z","timestamp":1762272303225,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.exphem.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T12:30:41Z","timestamp":1533126641000},"page":"50-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia"],"prefix":"10.1016","volume":"66","author":[{"given":"Camilla de S.","family":"Borges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline F.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor H.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto G.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gabriela","family":"Berzoti-Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira da Costa","family":"Cacemiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia S.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena L.","family":"Figueiredo-Pontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda P.","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fab\u00edola A.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5260-2332","authenticated-orcid":false,"given":"Robson Q.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2018.07.008_bib0001","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.07.008_bib0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2018.07.008_bib0003","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1038\/sj.onc.1206082","article-title":"BCR\/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia","volume":"21","author":"Salesse","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.07.008_bib0004","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.008_bib0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2018.07.008_bib0006","first-page":"89","article-title":"Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia","volume":"1","author":"Ebos","year":"2002","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0007","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2002-01-0109","article-title":"BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin","volume":"100","author":"Mayerhofer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.008_bib0008","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.01.005","article-title":"Current approach to the treatment of chronic myeloid leukaemia","volume":"55","author":"Pasic","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.008_bib0011","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.008_bib0012","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.exphem.2018.07.008_bib0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib resistance","volume":"4","author":"Quentmeier","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2018.07.008_bib0015","doi-asserted-by":"crossref","unstructured":"Rumjanek VM, Vidal RS, Maia RC. Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR\u2013CML cell lines? Biosci Rep. 2013;33:875\u2013888.","DOI":"10.1042\/BSR20130067"},{"key":"10.1016\/j.exphem.2018.07.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129648","article-title":"Clonal evolution and blast crisis correlate with enhanced proteolytic activity of separase in BCR-ABL b3a2 fusion type CML under imatinib therapy","volume":"10","author":"Haa\u00df","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2018.07.008_bib0017","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.07.008_bib0018","doi-asserted-by":"crossref","first-page":"38717","DOI":"10.18632\/oncotarget.16314","article-title":"Contributions of MET activation to BCR\u2013ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells","volume":"8","author":"Tsubaki","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2018.07.008_bib0019","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.exphem.2018.07.008_bib0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1152\/physrev.00028.2003","article-title":"Protease-activated receptors: contribution to physiology and disease","volume":"84","author":"Ossovskaya","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1016\/j.exphem.2018.07.008_bib0021","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1042\/BSR20130057","article-title":"Activation of blood coagulation in cancer: implications for tumour progression","volume":"33","author":"Lima","year":"2013","journal-title":"Biosci Rep"},{"key":"10.1016\/j.exphem.2018.07.008_bib0022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10555-015-9599-4","article-title":"Protease-activated receptors (PARs)\u2013: biology and role in cancer invasion and metastasis","volume":"34","author":"Wojtukiewicz","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.exphem.2018.07.008_bib0023","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bcmd.2010.12.005","article-title":"Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias","volume":"46","author":"Veiga","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.exphem.2018.07.008_bib0024","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","article-title":"Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL","volume":"16","author":"Amarante-Mendes","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.07.008_bib0025","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1016\/S0021-9258(17)37225-3","article-title":"Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production","volume":"269","author":"Mari","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.07.008_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5414\/CPP40329","article-title":"Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro","volume":"40","author":"Schiller","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.exphem.2018.07.008_bib0027","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/sj.leu.2402486","article-title":"Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants","volume":"16","author":"Janowska-Wieczorek","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.07.008_bib0028","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1096\/fj.02-0316com","article-title":"Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation","volume":"17","author":"Yin","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.exphem.2018.07.008_bib0029","doi-asserted-by":"crossref","first-page":"9835","DOI":"10.1158\/0008-5472.CAN-07-1886","article-title":"Transcriptional regulation of human protease-activated receptor 1: a role for the early growth response-1 protein in prostate cancer","volume":"67","author":"Salah","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2009-10-250639","article-title":"Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells","volume":"116","author":"Magnus","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.008_bib0031","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1038\/onc.2008.324","article-title":"p53 controls hPar1 function and expression","volume":"27","author":"Salah","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.07.008_bib0032","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3892\/or.2013.2880","article-title":"Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin\u20138 in human astrocytoma patients","volume":"31","author":"Carneiro-Lobo","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.exphem.2018.07.008_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110682","article-title":"BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia","volume":"9","author":"Panuzzo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2018.07.008_bib0034","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12885-016-2346-6","article-title":"The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase","volume":"16","author":"Crivellaro","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2018.07.008_bib0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.beha.2009.08.002","article-title":"New targets for Ph+ leukaemia therapy","volume":"22","author":"Martinelli","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2018.07.008_bib0036","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","article-title":"Specific inhibition of bcr\u2013abl gene expression by small interfering RNA","volume":"101","author":"Scherr","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.008_bib0037","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.gt.3302328","article-title":"Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy","volume":"12","author":"Scherr","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.exphem.2018.07.008_bib0038","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10238-007-0125-z","article-title":"Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Koldehoff","year":"2007","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.exphem.2018.07.008_bib0039","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia: signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2018.07.008_bib0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000369446","article-title":"Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy","volume":"133","author":"Ferreira","year":"2015","journal-title":"Acta Haematol"},{"key":"10.1016\/j.exphem.2018.07.008_bib0041","article-title":"The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia","volume":"2012","author":"Nestal de Moraes","year":"2012","journal-title":"Leuk Res Treatment"},{"key":"10.1016\/j.exphem.2018.07.008_bib0042","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1541-7786.MCR-06-0261","article-title":"Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression","volume":"5","author":"Salah","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0043","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jcb.20533","article-title":"PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism","volume":"96","author":"Tantivejkul","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.exphem.2018.07.008_bib0044","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1158\/0008-5472.CAN-09-0187","article-title":"Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2018.07.008_bib0046","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1038\/onc.2016.416","article-title":"Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia","volume":"36","author":"Goyama","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.07.008_bib0047","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1038\/onc.2015.452","article-title":"PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo","volume":"35","author":"Auvergne","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.07.008_bib0048","doi-asserted-by":"crossref","unstructured":"Schmidt T, Carmeliet P. Angiogenesis: a target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program. 2011;2011:1\u20138.","DOI":"10.1182\/asheducation-2011.1.1"},{"key":"10.1016\/j.exphem.2018.07.008_bib0049","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/138945007779940089","article-title":"Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies","volume":"8","author":"Kessler","year":"2007","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.exphem.2018.07.008_bib0050","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3892\/or.2012.2045","article-title":"Role of VEGF\/VEGFR in the pathogenesis of leukemias and as treatment targets","volume":"28","author":"Song","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.exphem.2018.07.008_bib0051","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1309\/3JLTFNNEDQHB4A0P","article-title":"Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leucemia and correlation with the phase of disease","volume":"121","author":"Krauth","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.exphem.2018.07.008_bib0052","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood.V99.6.2265","article-title":"Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leucemia","volume":"99","author":"Verstovsek","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.008_bib0053","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/147323000903700218","article-title":"Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells","volume":"37","author":"Li","year":"2009","journal-title":"J Int Med Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0054","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/jpet.105.099069","article-title":"Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis","volume":"318","author":"Zania","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2018.07.008_bib0055","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","article-title":"Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia","volume":"55","author":"Jabbour","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2018.07.008_bib0056","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.07.008_bib0057","first-page":"1648","article-title":"Prognostic relevance of protease-activated receptor-1 (PAR-1) expression in acute leukemia patients","volume":"49","author":"Aref","year":"2015","journal-title":"Int J Cancer Res"},{"key":"10.1016\/j.exphem.2018.07.008_bib0058","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.029","article-title":"Prognostic value of protease activated receptor-1 in children with acute lymphoblastic leukemia","volume":"6","author":"Hagag","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.exphem.2018.07.008_bib0059","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-L\u00f3pez MT, Guti\u00e9rrez-Rodr\u00edguez M, Herranz R. Thrombin-activated receptors: promising targets for cancer therapy? Curr Med Chem. 2010;17:109\u2013128.","DOI":"10.2174\/092986710790112639"},{"key":"10.1016\/j.exphem.2018.07.008_bib0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tips.2017.05.001","article-title":"Targeting PAR1: now what?","volume":"38","author":"Flaumenhaft","year":"2017","journal-title":"Trends Pharmacol Sci"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1830746X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1830746X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:33:46Z","timestamp":1759566826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X1830746X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":60,"alternative-id":["S0301472X1830746X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2018.07.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}